Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032301 · ClinicalTrials.gov registry record · Phase 1
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT04032301 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 67 participants.
The verdict
NCT04032301, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.
Interventions
- DRUG Ketamine
- OTHER Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2024-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032301
The ClinicalTrials.gov registry entry for NCT04032301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT04032301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032301 about?
NCT04032301 is a clinical study titled "Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans". Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk ...
What is the current status of trial NCT04032301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2019-09-30. Estimated completion is 2024-11-10.
What interventions are being tested in trial NCT04032301?
The interventions under investigation include: Ketamine (DRUG), Normal Saline (OTHER).
Who is sponsoring clinical trial NCT04032301?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.